US 11,666,610 B2
Probiotic formulations for improving athletic performance
Jonathan Scheiman, Brighton, MA (US); and George M. Church, Brookline, MA (US)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US)
Filed by President and Fellows of Harvard College, Cambridge, MA (US)
Filed on Apr. 18, 2022, as Appl. No. 17/722,459.
Application 17/722,459 is a continuation of application No. 17/395,588, filed on Aug. 6, 2021, granted, now 11,324,783.
Application 17/395,588 is a continuation of application No. 16/092,080, granted, now 11,090,342, issued on Aug. 17, 2021, previously published as PCT/US2017/026773, filed on Apr. 10, 2017.
Claims priority of provisional application 62/320,787, filed on Apr. 11, 2016.
Prior Publication US 2022/0241351 A1, Aug. 4, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/741 (2015.01); A61K 35/748 (2015.01); C12N 1/20 (2006.01); A23L 33/135 (2016.01); A23C 9/123 (2006.01); A61K 35/744 (2015.01); C12Q 1/02 (2006.01); C12Q 1/689 (2018.01); A61K 35/00 (2006.01)
CPC A61K 35/741 (2013.01) [A23C 9/123 (2013.01); A23L 33/135 (2016.08); A61K 35/744 (2013.01); A61K 35/748 (2013.01); C12N 1/20 (2013.01); C12Q 1/025 (2013.01); C12Q 1/689 (2013.01); A23V 2002/00 (2013.01); A61K 2035/115 (2013.01); C12Q 2600/158 (2013.01)] 30 Claims
OG exemplary drawing
 
1. A composition formulated for administration to a human, comprising bacteria of the genera Veillonella and Lactobacillus.